201 related articles for article (PubMed ID: 24535624)
21. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
22. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
23. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
Buse JB; Sesti G; Schmidt WE; Montanya E; Chang CT; Xu Y; Blonde L; Rosenstock J;
Diabetes Care; 2010 Jun; 33(6):1300-3. PubMed ID: 20332351
[TBL] [Abstract][Full Text] [Related]
24. Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
Scott LJ
Drugs; 2012 Aug; 72(12):1679-707. PubMed ID: 22867046
[TBL] [Abstract][Full Text] [Related]
25. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
Blonde L; Pencek R; MacConell L
Cardiovasc Diabetol; 2015 Feb; 14():12. PubMed ID: 25645567
[TBL] [Abstract][Full Text] [Related]
26. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
[TBL] [Abstract][Full Text] [Related]
27. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
[TBL] [Abstract][Full Text] [Related]
28. Evolution of exenatide as a diabetes therapeutic.
Bhavsar S; Mudaliar S; Cherrington A
Curr Diabetes Rev; 2013 Mar; 9(2):161-93. PubMed ID: 23256660
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
Molina Vega M; Muñoz-Garach A; Tinahones FJ
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
[TBL] [Abstract][Full Text] [Related]
30. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.
Best JH; Boye KS; Rubin RR; Cao D; Kim TH; Peyrot M
Diabet Med; 2009 Jul; 26(7):722-8. PubMed ID: 19573122
[TBL] [Abstract][Full Text] [Related]
31. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
32. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
Rosenstock J; Balas B; Charbonnel B; Bolli GB; Boldrin M; Ratner R; Balena R;
Diabetes Care; 2013 Mar; 36(3):498-504. PubMed ID: 23139373
[TBL] [Abstract][Full Text] [Related]
33. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
Murphy CE
Ann Pharmacother; 2012 Jun; 46(6):812-21. PubMed ID: 22669803
[TBL] [Abstract][Full Text] [Related]
34. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
[TBL] [Abstract][Full Text] [Related]
35. [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014; 143 Suppl 2():23-7. PubMed ID: 25326840
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS; Mace KF; Diamant M; Darsow T; Cirincione BB; Booker Porter TK; Kinninger LA; Trautmann ME
Diabetes Obes Metab; 2012 Jun; 14(6):546-54. PubMed ID: 22236356
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
38. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
Davies M; Heller S; Sreenan S; Sapin H; Adetunji O; Tahbaz A; Vora J
Diabetes Care; 2013 May; 36(5):1368-76. PubMed ID: 23275363
[TBL] [Abstract][Full Text] [Related]
39. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
